Fostamatinib disodium: Tyrosine-protein kinase SYK/FLT3 inhibitor treatment of rheumatoid arthritis oncolytic

Drugs of the Future

Volumn 36, Issue 4, 2011, Pages 273-280

  McAdoo, S P ^a   Tam, F W K ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; FC RECEPTOR; FOSTAMATINIB; METHOTREXATE; NSC 745942; PROTEIN KINASE SYK INHIBITOR; RITUXIMAB; UNCLASSIFIED DRUG;

ALLERGY; ARTHRITIS; ASTHMA; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BRONCHUS HYPERREACTIVITY; CELL TYPE; DIABETES MELLITUS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; EFFECTOR CELL; FETUS MALFORMATION; GASTROINTESTINAL TOXICITY; GLOMERULONEPHRITIS; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOTOXICITY; INFLAMMATION; INSULITIS; KIDNEY INJURY; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LEUKEMIA; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 84952976693     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.04.1588554     Document Type: Review

References (39)

1. Singh, R., Atuegbu, A., Ramphal, J. et al. (Rigel Pharmaceuticals, Inc.). Pyrimidinediamine kinase inhibitors. US 2010179134, WO 2010078369.
2. Felfer, U., Giselbrecht, K.-H., Wolberg, M. (Rigel Pharmaceuticals, Inc.). Synthesis of N4-(2,2-dimethyl-4-[dihydrogen phosphonoxy]-3-oxo-5- pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2, 4-pyrimidinediamine disodium salt. US 2011003986, WO 2011002999.
3. Bhamidipati, S., Singh, R., Sun, T., Masuda, E. (Rigel Pharmaceuticals, Inc.). Prodrug salts of 2,4-pyrimidinediamine compounds and their uses. EP 2078026, JP 2010510322, WO 2008064274.
4. Singh, R., Bhamidipati, S., Masuda, E., Stella, V.J., Sun, T. (Rigel Pharmaceuticals, Inc.). Prodrugs of 2,4-pyrimidinediamine compounds and their uses. CA 2591948, EP 1856135, EP 2161275, JP 2008527048, US 2006211657, US 7449458, WO 2006078846.
5. Singh, R., Bhamidipati, S., Stella, V.J., Sun, T. (Rigel Pharmaceuticals, Inc.). Prodrugs of 2,4-pyrimidinediamine compounds and their uses. US 7563892.
6. Taniguchi, T., Kobayashi, T., Kondo, J. et al. Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem 1991, 266(24): 15790-6. (Pubitemid 21907727)
7. Turner, M., Schweighoffer, E., Colucci, F., Di Santo, J.P., Tybulewicz, V.L. Tyrosine kinase SYK: Essential functions for immunoreceptor signalling. Immunol Today 2000, 21(3): 148-54. (Pubitemid 30122705)
8. Mocsai, A., Ruland, J., Tybulewicz, V.L. The SYK tyrosine kinase: A crucial player in diverse biological functions. Nat Rev Immunol 2010, 10(6): 387-402.
9. Braselmann, S., Taylor, V., Zhao, H. et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006, 319(3): 998-1008.
10. Cha, H.S., Boyle, D.L., Inoue, T., Schoot, R., Tak, P.P., Pine, P., Firestein, G.S. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006, 317(2): 571-8.
11. Buchner, M., Fuchs, S., Prinz, G. et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res 2009, 69(13): 5424-32.
12. Chen, L.,Monti, S., Juszczynski, P. et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008, 111(4): 2230-7. (Pubitemid 351451430)
13. Quiroga, M.P., Balakrishnan, K., Kurtova, A.V. et al., B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: Specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009, 114(5): 1029-37.
14. Buchner, M., Baer, C., Prinz, G. et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood, 2010, 115(22): 4497-506.
15. Valera, I., et al., Costimulation of dectin-1 and DC-SIGN triggers the arachidonic acid cascade in human monocyte-derived dendritic cells. J Immunol 2008, 180(8): 5727-36.
16. Matsubara, S., Koya, T., Takeda, K. et al. Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol, 2006, 34(4): p. 426-33.
17. Colonna, L., Catalano, G., Chew, C. et al. Therapeutic targeting of Syk in autoimmune diabetes. J Immunol 2010, 185(3): 1532-43.
18. Sanderson, M.P., Gelling, S.J., Rippmann, J.F., Schnapp, A. Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcepsilonRI-activated RBL-2H3 basophilic cells. Cell Immunol 2010, 262(1): 28-34.
19. Krishnan, S., Juang, Y.T., Chowdhury, B. et al. Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol 2008, 181(11): 8145-52.
20. thAnnu Meet Am Soc Hematol (December 10-13, Atlanta) 2005], 2005, 106(11): Abst 243.
21. Spalton, J.C., Mori, J., Pollitt, A.Y., Hughes, C.E., Eble, J.A., Watson, S.P. The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets. J Thromb Haemost 2009, 7(7): 1192-9.
22. Suljagic, M., Longo, P.G., Bennardo, S., Perlas, E., Leone, G., Laurenti, L., Efremov, D.G. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 2010, 116(23): 4894-905.
23. Young, R.M., Hardy, I.R., Clarke, R.L. et al. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 2009, 113(11): 2508-16.
24. Podolanczuk, A., Lazarus, A.H., Crow, A.R., Grossbard, E., Bussel, J.B. Of mice and men: An open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009, 113(14): 3154-60.
25. Matsubara, S., Li, G., Takeda, K. et al. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med 2006, 173(1): 56-63. (Pubitemid 43069788)
26. Pine, P.R., Chang, B., Schoettler, N. et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 2007, 124(3): 244-57. (Pubitemid 47247604)
27. Bahjat, F.R., Pine, P.R., Reitsma, A. et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 2008, 58(5): 1433-44. (Pubitemid 351705932)
28. Deng, G.M., Liu, L., Bahjat, F.R., Pine, P.R., Tsokos, G.C. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum 2010, 62(7): 2086-92.
29. Smith, J., McDaid, J.P., Bhangal, G. et al. A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. J Am Soc Nephrol 2010, 21(2): 231-6.
30. Pamuk, O.N., Lapchak, P.H., Rani, P., Pine, P., Dalle Lucca, J.J., Tsokos, G.C. Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion. Am J Physiol Gastrointest Liver Physiol 2010, 299(2): G391-9.
31. Friedberg, J.W., Sharman, J., Sweetenham, J. et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115(13): 2578-85.
32. Weinblatt, M.E., Kavanaugh, A., Burgos-Vargas, R. et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008, 58(11): 3309-18.
33. Sweeny, D.J., Li, W., Clough, J. et al. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: Contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab Dispos 2010, 38(7): 1166-76.
34. Zhu, Y., Herlaar, E., Masuda, E.S., Burleson, G.R., Nelson, A.J., Grossbard, E.B., Clemens, G.R. Immunotoxicity assessment for the novel spleen tyrosine kinase inhibitor R406. Toxicol Appl Pharmacol 2007, 221(3): 268-77. (Pubitemid 46855812)
35. Weinblatt, M.E., Kavanaugh, A., Genovese, M.C., Musser, T.K., Grossbard, E.B., Magilavy, D.B. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010, 363(14): 1303-12.
36. Genovese, M.C., Kavanaugh, A., Weinblatt, M.E. et al. An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritisthat did not respond to biologic agents. Arthritis Rheum 2010, 63(2): 337-45.
37. Clemens, G.R., Schroeder, R.E., Magness, S.H. et al. Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing. Birth Defects Res A Clin Mol Teratol 2009, 85(2): 130-6.
38. th Annu Sci Meet Am Coll Rheumatol (Nov 12-17, San Diego) 2005] 2005, 52(9): Abst 1864.
39. Grossbard, E., Baluom, M., Kivitz, A.J. A phase I randomized, double-blind, placebo-controlled, pharmacokinetic study of R788/406 and methotrexate in sixteen patients with rheumatoid arthritis. Arthritis Rheum 2006, 54(9, Suppl.): Abst 939.